Bristol-Myers Squibb Company
Marktkapitalisatie
$132.0B
Wereldwijde rang
#127
Recordhoogte
$134.6B
2026-08-04
Totale groei
+0%
sinds 2026
Market Cap Context
- Larger than 65% of the 367 companies we track (globally).
- Equivalent to 0.4% of United States's GDP (2025 data).
- Just above: #126 Prologis, Inc. ($133.6B)
- Just below: #128 BNP Paribas SA ($131.6B)
- Best year: 1997 (+78%). Worst year: 2002 (-53%).
Bristol-Myers Squibb Company Financial Breakdown (FY 2025)
Source: Yahoo Finance โ BMY annual filings (2025) โ$48.2B revenue ยท $13.7B operating income ยท $7.1B net income
- โOperating margin: 28.5% on $48.2B in revenue.
- โR&D is 20.6% of revenue ($10.0B).
- โNet income margin: 14.6% โ $7.1B in profit.
- โFree cash flow: $12.8B (26.7% of revenue).
Cost / Operating Expenses
Total operating expenses $34.5B
Total
$31.2B
Capital Expenditures
$1.3B
This fiscal year (near-total AI infrastructure buildout)
Free Cash Flow
$12.8B
Trailing twelve months
Figures rounded from the annual SEC filing. Unaudited. For informational purposes only, not investment advice.
Over Bristol-Myers Squibb Company
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban (Eliquis) for people with atrial fibrillation ; nivolumab (Opdivo), used to treat certain types of cancer ; lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes ; abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid arthritis ; pomalidomide (Pomalyst/Imnovid), an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma ; ipilimumab (Yervoy), to treat cancer ; and luspatercept (Reblozyl) for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2025, 69% of the company's revenues came from the United States.
Marktkapitalisatiegeschiedenis van Bristol-Myers Squibb Company (2026โ2026)
Bristol-Myers Squibb Company vs Sector Peers by Market Cap
Bristol-Myers Squibb Company vergelijken
Ranggeschiedenis
| Jaar | Marktkapitalisatie | Rang | Verandering op jaarbasis |
|---|---|---|---|
| 2026 | $132.0B | #127(โ12) | +22.5% |
| 2025 | $107.8B | #139(โ15) | +0.1% |
| 2024 | $107.6B | #124(โ3) | +15.8% |
| 2023 | $92.9B | #121(โ53) | -26.1% |
| 2022 | $125.8B | #68(โ26) | +19.0% |
| 2021 | $105.8B | #94(โ13) | +3.7% |
| 2020 | $102.0B | #81(โ14) | -0.4% |
| 2019 | $102.4B | #67(โ6) | +27.7% |
| 2018 | $80.2B | #61(โ9) | -12.9% |
| 2017 | $92.0B | #52(โ6) | +7.7% |
| 2016 | $85.4B | #46(โ17) | -13.0% |
| 2015 | $98.2B | #29(โ11) | +19.3% |
| 2014 | $82.3B | #40(โ2) | +14.2% |
| 2013 | $72.0B | #42(โ16) | +68.8% |
| 2012 | $42.7B | #58(โ15) | -3.8% |
| 2011 | $44.4B | #43(โ24) | +39.4% |
| 2010 | $31.8B | #67 | +10.1% |
| 2009 | $28.9B | #67(โ14) | +15.0% |
| 2008 | $25.1B | #53(โ28) | -7.3% |
| 2007 | $27.1B | #81(โ13) | +4.8% |
| 2006 | $25.9B | #68(โ4) | +19.9% |
| 2005 | $21.6B | #72(โ11) | -6.1% |
| 2004 | $23.0B | #61(โ15) | -6.3% |
| 2003 | $24.5B | #46(โ3) | +29.4% |
| 2002 | $19.0B | #43(โ18) | -53.0% |
| 2001 | $40.3B | #25(โ4) | -26.2% |
| 2000 | $54.6B | #21(โ4) | +17.1% |
| 1999 | $46.6B | #25(โ8) | -2.8% |
| 1998 | $48.0B | #17(โ2) | +43.6% |
| 1997 | $33.4B | #19(โ9) | +77.5% |
| 1996 | $18.8B | #28(โ2) | +31.2% |
| 1995 | $14.3B | #26(โ1) | +55.2% |
| 1994 | $9.2B | #25 |
Andere bedrijven in de sector Gezondheidszorg
Veelgestelde vragen
What is Bristol-Myers Squibb Company's market cap?
Bristol-Myers Squibb Company (BMY) has a market capitalization of $132.0B, making it the #127 largest company in the world by market cap.
What was Bristol-Myers Squibb Company's highest market cap?
Bristol-Myers Squibb Company's all-time high market cap was $134.6B, reached in 2026-08-04. Its highest rank was #127 in 2026.
What sector is Bristol-Myers Squibb Company in?
Bristol-Myers Squibb Company is in the Healthcare sector, specifically the Drug Manufacturers - General industry. It is based in United States.
How has Bristol-Myers Squibb Company's market cap changed over time?
Bristol-Myers Squibb Company has been tracked since 2026. Its market cap has grown by 0% from $132.0B in 2026 to $132.0B today.